Multimodal Kidney Mechanisms of SGLT2 Inhibition in Patients with Type 1 Diabetes
Résumé fourni par la source
Background: SGLT2 inhibitors slow chronic kidney disease progression, but intrarenal mechanisms in type 1 diabetes (T1D) remain unclear. Methods: Single-cell RNA-seq (scRNA-seq) from paired kidney biopsies (subcohort, Fig.) and multiparametric kidney MRI (BOLD R2*) were obtained at baseline and after 16 weeks of treatment with dapagliflozin (dapa) or placebo in youth with T1D and preserved kidney function in a pre-specified ancillary study of the ATTEMPT trial (N=98). Transcriptomic effects were tested with negative binomial mixed models (NBMM) with fixed effects of treatment, visit, their interaction, and within-subject correlation, with FDR<0.05. Transcript changes were regressed against changes in iohexol mGFR, HbA1c and time-in-range (TIR), adjusting for treatment effects within each cell type. An independent external cohort of youth with T1D and healthy controls was used to test whether dapa-responsive transcripts shifted toward healthy-control levels. Results: Dapa reduced GFR, lowered HbA1c, and increased TIR, as previously published. MRI showed increased whole-kidney R2* (p=0.03), consistent with reversal of diabetic medullary hyperoxia (p<0.001). scRNA-seq from 27 biopsies (~214k cells) revealed placebo-controlled shifts across nephron segments, especially PT, TAL, EC, IC, and POD (q<0.001; Fig.). Pseudotime trajectories indicated a shift from stress-prone PT toward healthier PT states. In the external T1D cohort, ~55% of shared significant dapa-responsive transcripts moved toward healthy-control levels. Conclusion: SGLT2 inhibition engages convergent kidney mechanisms in T1D including metabolic reprogramming, vascular quiescence, improved oxygen handling, and acid–base adaptation, providing causal, multimodal evidence for mechanisms underlying kidney protection. Funding: Private Foundation Support
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Multimodal Kidney Mechanisms of SGLT2 Inhibition in Patients with Type 1 Diabetes
- Date Crossref
- 01/10/2025
- Éditeur
- Ovid Technologies (Wolters Kluwer Health)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude et ne compte pas comme une seconde source scientifique indépendante.
Institutions déclarées
Une affiliation ne permet pas de déduire la nationalité d’un auteur.